SCHEMBL4350092

SCHEMBL4350092

CC(=O)c1cc(Cl)cc(NCc2ccccc2Sc2ccc3cccnc3c2)c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 4/20 0.38
KMT2A Q03164 6/20 0.35
MEN1 O00255 5/20 0.35
CASP6 P55212 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 4/20 0.34
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
ALDH1A1 P00352 2/20 0.34
NSD2 O96028 1/20 0.34
BLM P54132 1/20 0.34
NR4A2 P43354 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
KDR P35968 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12846760 0.91 CTSD (0.35) CTSDKMT2AMEN1CASP6SMN1; SMN2
SCHEMBL4347116 0.87 GAA (0.43) CTSDKMT2AMEN1CASP6MAPT
SCHEMBL4347491 0.86 CTSD (0.40) CTSDKMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL4347953 0.84 KMT2A (0.35) CTSDKMT2AMEN1CASP6SMN1; SMN2
SCHEMBL4351160 0.84 SLC6A4 (0.43) KMT2AMEN1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL6225665 0.84 MEN1 (0.38) CTSDKMT2AMEN1CASP6MAPT
SCHEMBL4353891 0.83 SMN1; SMN2 (0.39) CTSDSMN1; SMN2ALDH1A1BLMHPGD
SCHEMBL4349809 0.83 SMN1; SMN2 (0.43) KMT2AMEN1SMN1; SMN2MAPTKDM4E
SCHEMBL4341844 0.83 MEN1 (0.41) KMT2AMEN1CASP6SMN1; SMN2MAPT
SCHEMBL4347133 0.82 KMT2A (0.51) KMT2AMEN1CASP6MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 CTSD 2659/4885KMT2A 2096/4885MEN1 2168/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 CTSD 2112/4885KMT2A 1254/4885MEN1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.